Investors are paying attention to the progress of FT606. Shandong Lukang Pharmaceutical did not directly respond to the production time | Live coverage of the earnings conference

① The company's new synthetic biotechnology material product FT606 has attracted much attention. ② The pharmaceutical industry was in the traditional off-season in the third quarter, leading to a decline in the company's Q3 performance. ③ In the earnings conference, a questioner claiming to be an investor expressed dissatisfaction with the lack of interaction.

cls.cnNov 8 08:51 ET

Jiangsu Hengrui Pharmaceuticals' Q3 revenue was 6.59 billion yuan, with a net income of 1.19 billion yuan, a slight year-on-year increase of 1.9%. | Financial Report Watch

In the third quarter, jiangsu hengrui pharmaceuticals' eps was 0.19 RMB, a year-on-year increase of 5.56%. In the first three quarters, jiangsu hengrui pharmaceuticals' profit increased by 32.98% year-on-year, with eps increasing by 32.73% year-on-year. The main reason is that the company recognized the upfront payment received from Merck Healthcare of 0.16 billion euros as revenue, which significantly increased the profit.

wallstreetcnOct 24 07:58 ET

From cspc innovation pharmaceutical to Stone Medicine Innovation, what has changed is not just the R&D expenses.

From active pharmaceutical ingredients to innovative drugs, from focusing on current profits to focusing on product pipeline and cash flow.

wallstreetcnOct 24 04:25 ET

"Pharmaceuticals king" for financing or listing in Hong Kong? Jiangsu Hengrui Pharmaceuticals has no comment on the rumors.

①There were reports last night that jiangsu hengrui pharmaceuticals is considering a secondary listing in Hong Kong next year, with an expected fundraising amount of 2 billion US dollars. In response, jiangsu hengrui pharmaceuticals stated that they have no comments; ② Industry insiders believe that a secondary listing in Hong Kong can not only raise funds but also enhance the company's international influence.

cls.cnOct 24 01:29 ET

Market rotation between high and low speeds up! The new energy fund track collectively warms up, and the direction of mergers and reorganizations favors the strong.

Track the entire lifecycle of the main sector.

cls.cnOct 23 21:21 ET

Pharmaceutical business shrinks, livzon pharmaceutical group inc. revenue declines year-on-year in the first three quarters | interpretations

1. In the first three quarters of this year, livzon pharmaceutical group inc.'s revenue decreased by a single-digit percentage compared to the same period last year, while net profit attributable to shareholders maintained positive growth year-on-year; 2. The revenue of the pharmaceutical sector, which contributed the most, declined; 3. Semaglutide has been submitted for marketing approval for the indication of diabetes, and the development of weight loss indication has entered phase III clinical trials.

cls.cnOct 23 09:27 ET